title: Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer".
authors.affiliation: KatahdinRX Oncology, Bowdoinham, Maine. laura@KatahdinRx.com.
authors.forename: Laura E
authors.initials: LE
authors.lastname: Benjamin
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics; D061067:Antibodies, Monoclonal, Humanized / Q000235:genetics; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068818:Cetuximab; D015179:Colorectal Neoplasms; D006801:Humans; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018631:ras Proteins / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011518:Proto-Oncogene Proteins; D018631:ras Proteins; D000068818:Cetuximab